This proposal received 36.2% support at the 2025 annual meeting, which is in the 30-40% range — a moderate signal that warrants evaluation on the merits rather than a strong presumption in favor. After the 2025 vote, Gilead proactively engaged with shareholders representing 42% of outstanding shares, and the proxy reports that most investors expressed support for the current combined Chairman/CEO structure with a robust Lead Independent Director role. The Lead Independent Director at Gilead holds comprehensive, substantive responsibilities explicitly modeled on those of an independent chair — including agenda approval, running executive sessions, liaising between independent directors and management, participating in CEO succession planning, and direct stockholder engagement — which meaningfully reduces the governance gap that an independent chair policy is typically designed to address. At 36% prior-year support and with credible, documented investor engagement showing majority satisfaction with the current structure, the balance of evidence does not support requiring a structural change at this time.

This proposal asks Gilead to report on the risks that extended patent exclusivities pose to patient access. While access-to-medicine is a material topic for a pharmaceutical company, Gilead already discloses extensive information on its access programs — including royalty-free voluntary licensing agreements covering 120 countries, a PEPFAR partnership to supply lenacapavir to up to two million people, and its corporate responsibility reporting framework. The proposal appears to frame standard patent protection as a risk requiring special disclosure, which goes beyond a neutral request for transparency and into operational territory that could pressure the company to limit its intellectual property practices. Without a prior-year vote history showing material shareholder concern, and given the breadth of existing access-related disclosure, the proposal does not clear the bar for support under the lower-threshold disclosure category.

A proposal requesting a report on the 'risks' of ESG and DEI compensation metrics is a hallmark of conservative ideological advocacy — it frames standard compensation practices through a political lens rather than as a genuine shareholder fiduciary concern. Under the policy's symmetry rule, proposals motivated by ideological goals from either direction are voted against, regardless of how they are framed. A neutral fiduciary investor would not single out ESG and DEI metrics for special risk reporting while ignoring other compensation metrics; this proposal only makes sense as political advocacy. Vote AGAINST.